Horizon Discovery Group plc Block Listing Application (7395L)
July 24 2017 - 1:00AM
UK Regulatory
TIDMHZD
RNS Number : 7395L
Horizon Discovery Group plc
24 July 2017
24 July 2017
Horizon Discovery Group plc
Block Listing Application
The Company today announces that an application has been made to
the London Stock Exchange for a block admission of 3,000,000 new
ordinary shares of 1p each in the Capital of the Company ("New
Ordinary Shares") to be admitted to trading on AIM (the "Block
Admission"). It is expected that Admission will occur on 26 July
2017.
These New Ordinary Shares shall be issued and allotted from time
to time pursuant to the exercise of share options under the
following share schemes:
-- Horizon Discovery Limited Enterprise Management Incentive
Share Option Scheme (up to 1,398,000 shares)
-- Horizon Discovery Group plc Long Term Incentive Plan (up to 1,392,000 shares)
-- Horizon Discovery 2014 Sharesave Scheme (up to 110,000 shares)
-- Horizon Discovery Group plc US Employee Stock Purchase Plan (up to 100,000 shares)
The new ordinary shares, when issued, will rank pari passu with
the existing shares of the Company.
Following admission, the Company's issued share capital remains
unchanged at 96,571,853. The Company will make six-monthly
announcements of the utilisation of the Block Admission, in line
with its obligations under AIM Rule 29.
For further information, please contact:
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able
to alter almost any gene sequence in human or mammalian
cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and animal models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by over 1,600 unique research organisations in over 50
countries as well as in the Company's own R&D pipeline to
support a greater understanding of the genetic drivers of disease
and the development of molecular, cell and gene therapies that can
be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSLIFITDAILFID
(END) Dow Jones Newswires
July 24, 2017 02:00 ET (06:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024